Agendia

Agendia is a leading molecular diagnostics company focused on improving the quality of life for breast cancer patients by developing genomic tests to support physicians in making complex treatment decisions. Founded in 2003, they offer a suite of gene expression-based breast cancer tests that analyze a patient's tumor, providing their physician with unique genomic insight to personalize treatment. Their mission is to provide clarity and confidence on the path to recovery, believing in the power of genomic testing to better inform the patient journey.

Agendia is committed to advancing translational research, expanding access to their testing platforms, and building networks with leading academic institutions and cancer centers. They are also involved in a number of clinical trials, including I-SPY2 and the FLEX Study, that will ultimately impact how breast cancer is treated. Their research efforts have led to the development of MammaPrint and BluePrint, two commercially available genomic profiling tests that are supported by clinical and real-world evidence.

Agendia is a molecular diagnostics company dedicated to improving the quality of life for cancer patients by developing genomic tests that help physicians make more informed treatment decisions. Their mission is to provide clarity and confidence for patients on their path to recovery by leveraging the power of genomic testing to shed light on complex treatment decisions, leading to the most relevant and targeted approach for each individual. Their ultimate goal is to improve patient outcomes and quality of life, while also reducing unnecessary costs to the healthcare system.

Agendia promotes a culture of innovation, collaboration, and patient-centricity. They are dedicated to pushing the boundaries of personalized medicine in breast cancer and achieving better outcomes for patients. This focus on patient well-being permeates the company, encouraging employees to work together as a team to deliver high-quality genomic tests and research that can empower physicians and patients to make informed treatment decisions.

Agendia is committed to diversity, equity, and inclusion in its workforce and within the breast cancer community. The company emphasizes creating a culture of respect and belonging, recognizing the value of diverse perspectives. Agendia is actively engaged in research and advocacy initiatives to address disparities in breast cancer outcomes, particularly for Black women. Through its clinical trials, research partnerships, and patient advocacy programs, Agendia seeks to ensure that all patients have equitable access to its genomic tests and the personalized care they deserve.